成纤维细胞衍生的人类工程结缔组织用于筛查应用

Executive Industry Relevance

This protocol enables reproducible generation of human-derived engineered connective tissues (ECT) in a 48-well format, providing a scalable 3D model for studying fibroblast behavior under defined biomechanical load. It supports mechanistic de-risking of antifibrotic targets by allowing parallel testing of pro-fibrotic factors and drug candidates, with quantitative readouts on tissue compaction, contraction, and stiffness. The system enhances predictive confidence in early discovery by modeling human-relevant tissue responses to pharmacological perturbations.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of fibroblast-to-myofibroblast transdifferentiation under controlled mechanical and biochemical conditions.
• Scientific Value: Supports functional validation of antifibrotic targets through dose-response analysis of compounds like Latrunculin A on tissue contraction and stiffness.
• Operational Value: Facilitates target de-risking by linking cytoskeletal mechanisms to tissue-level biomechanical outcomes in a human-relevant system.

Screening & Assay Development

• Scientific Value: Provides a standardized, high-throughput platform for screening compounds affecting tissue mechanics, with readouts on compaction, contraction, and elastic modulus.
• Operational Value: Enables parallel testing of up to 48 conditions per plate, supporting dose-response and time-course assays under consistent biomechanical loading.
• Operational Value: Uses defined, minimal components (collagen I, FGM, NaOH) to ensure reproducibility across laboratories and minimize batch variability.

Translational & Preclinical Research

• Scientific Value: Models human cardiac fibroblast responses in a 3D environment, improving translational relevance over 2D cultures for fibrosis mechanism studies.
• Scientific Value: Allows study of tissue-level phenotypes such as stiffness and extensibility, which correlate with pathological remodeling in fibrotic diseases.
• Operational Value: Supports longitudinal analysis of tissue dynamics over five days, enabling chronic compound exposure studies relevant to preclinical efficacy.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation to lead optimization, providing a human-relevant 3D assay for mechanism-of-action confirmation and phenotypic screening in fibrosis programs.

• Discovery Biology: Supports hypothesis testing of fibroblast-matrix interactions and pathway modulation under defined tensile load.
• Screening: Delivers quantitative, reproducible outputs (tissue diameter, contraction %, Young’s modulus) for hit validation and SAR progression.
• Analytics: Enables automated image-based analysis of tissue geometry and stress-strain profiling for objective, data-driven decision making.
• Translational Research: Bridges in vitro findings to pathophysiological relevance by measuring tissue stiffness and failure points analogous to fibrotic remodeling.
• Enterprise Reuse: The 48-well format and minimal reagent requirements allow integration into existing screening infrastructures with low adaptation cost.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by isolating cell-matrix contributions to tissue stiffening and contractility.
• Operational Value: Ensures assay reproducibility through standardized cell preparation, hydrogel mixing, and casting parameters.
• Strategic Value: Improves go/no-go decisions by providing early, human-predictive data on antifibrotic efficacy and target engagement.
• Portfolio Impact: Enables risk-adjusted prioritization of candidates based on dose-dependent effects on tissue mechanics and actin integrity.

Implementation Considerations

• Requires expertise in primary fibroblast culture, hydrogel handling, and sterile technique to ensure cell viability and matrix integrity.
• Dependent on access to a dynamic mechanical riometer with temperature-controlled bath and automated image analysis tools for biomechanical profiling.
• Necessitates standardization of cell seeding density (8.9 million cells/mL) and collagen neutralization across users to minimize variability in tissue formation.
• Adaptation to non-cardiac fibroblasts may require optimization of culture medium and loading conditions to reflect tissue-specific phenotypes.
• Limited to endpoints assessable via tissue geometry and tensile testing; molecular readouts require parallel sampling or fixation.

Biopharma FAQs